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The mammalian target of rapamycin (mTOR) inhibitor sirolimus is effective in reducing incidence of graft-
versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Agents that
inhibit the mTOR pathway are known to be associated with signiﬁcant and potentially dose-limiting toxic-
ities, including stomatitis. The objective of this study was to report the clinical features and management
outcomes of sirolimus-associated oral ulcers in the context of post-HSCT prophylaxis of GVHD. Seventeen
patients, from a study cohort of 967, who were treated with sirolimus as prophylaxis for GVHD after allo-
geneic HSCT at the Dana-Farber/Brigham and Women’s Cancer Center developed oral ulcers and were
referred to the oral medicine clinic for evaluation and treatment over a period of 6 years. Clinical charac-
teristics (appearance, anatomic site, size) and therapeutic outcomes (time to complete resolution) were
documented. Median time to onset of oral ulceration was 55 days after allogeneic HSCT (range, 6 to 387 days);
92.9% of ulcers were located on nonkeratinized mucosa, with the ventrolateral tongue the most common site
of involvement. Thirteen patients were treated with topical corticosteroid therapy; 12 of these patients also
required intralesional corticosteroid injections. Clinical improvement (resolution of the lesions and
improvement of symptoms) was noted in all cases, with no reported adverse events. Median time to complete
resolution after onset of therapy was 14 days (range, 2 to 70 days). Patients receiving sirolimus for GVHD
prophylaxis may develop painful oral ulcerations, which can be effectively managed with topical steroid
treatment. Further prospective studies are needed to better elucidate the incidence of this complication,
identify risk factors, and evaluate the effectiveness of interventions.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Sirolimus (Rapamune, Pﬁzer, Princeton, NJ) is a mam-
malian target of rapamycin (mTOR) inhibitor with immu-
nosuppressive properties [1]. Sirolimus binds uniquely to
FK-binding protein 12 and forms a complex with mTOR,
which inhibits the PTEN/PI3K/Akt and JAK pathways [2,3],
resulting in downregulation of IL-2 and IL-15 signaling and
reduced T and B lymphocyte proliferation [4-6]. Sirolimusdgments on page 508.
quests: Dr. Alessandro Villa, Division of
am and Women’s Hospital, 1620 Trem-
MA 02120.
.org (A. Villa).
14.11.680
ty for Blood and Marrow Transplantation.has beenwidely used to prevent graft rejection in solid organ
transplantation [7,8]. In renal transplantation, sirolimus-
containing prophylaxis regimens have demonstrated ad-
vantages compared with azathioprine with respect to both
decreasing the incidence and severity of rejection episodes,
as well as improvement in graft function [9]. More recently,
sirolimus has demonstrated efﬁcacy in preventing and
managing graft-versus-host-disease (GVHD) after allogeneic
hematopoietic stem cell transplantation (HSCT) [4,10-12].
The substitution of sirolimus for methotrexate combined
with a calcineurin inhibitor (tacrolimus) has demonstrated
similar effectiveness for GVHD prophylaxis and a signiﬁ-
cantly reduced incidence and severity of methotrexate-
associated toxicity, including oral mucositis [11,12].
A. Villa et al. / Biol Blood Marrow Transplant 21 (2015) 503e508504Sirolimus has a unique toxicity proﬁle, with the most
common side effects including hyperlipidemia, cytopenias,
impaired wound healing, interstitial pneumonitis, acneiform
rash, and aphthous-like oral ulcers [13-18]. The aphthous-
like oral ulcerations have been observed in several clinical
trials of sirolimus in renal transplantation, with an incidence
rate of up to 60% [17,19-21]. These oral mucosal ulcers pre-
sent as solitary or multiple lesions with rapid onset after
initiation of sirolimus therapy and are characterized by a
typical ovoid shapewith a central gray area surrounded by an
erythematous halo, affecting almost exclusively the non-
keratinized mucosa [22]. The lesions can be sufﬁciently
painful and debilitating to require discontinuation of siroli-
mus and substitution with an alternative immunosuppres-
sive agent [20]. Although this complication has been well
described in the context of solid organ transplantation, no
data are available on sirolimus-associated oral ulcers pre-
senting in the context of GVHD prophylaxis in HSCT. The
objective of this study was to characterize the clinical fea-
tures and management outcomes of sirolimus-associated
oral ulcers in patients undergoing allogeneic HSCT with
sirolimus-containing GVHD prophylaxis regimens.METHODS
A retrospective case record review was conducted of all patients at
Dana-Farber/Brigham and Women’s Cancer Center between March 2006
and October 2012 who underwent allogeneic HSCT and received sirolimus
for GVHD prophylaxis (n ¼ 967) and who developed symptomatic
aphthous-like oral mucosal lesions (typically round or ovoid with well-
demarcated borders and focal perilesional erythema) that required inter-
vention. This study was approved by the Dana-Farber/Harvard Cancer
Center’s Ofﬁce for Human Research Subjects.
All patients for whom records were reviewed had been referred to the
oral medicine practitioner (N.T.) by their transplantation oncologist for
diagnosis and management of painful oral ulcerations. Clinical diagnosis of
the oral mucosal lesions was based on characteristic aphthous-like features,
including shallow ovoid ulcers with perilesional erythema, largely res-
tricted to the unattached non-keratinized oral mucosa [18]. An incisional
biopsy was obtained in 5 patients to rule out other mucosal pathology.
Despite all patients receiving post-HSCT acyclovir prophylaxis, herpes
simplex virus culture was obtained in all cases to rule out breakthrough
recrudescence.Table 1
Patient Characteristics
Patient Age Gender Diagnosis Conditioning Stem Cell
Source
Matching aGVHD
1 54 M AML RIC BM MUD 
2 54 M CLL RIC UCB MUD 
3 58 F NHL RIC UCB MUD 
4 58 M NHL MAC UCB MUD 
5 61 M MDS RIC PBSC MUD 
6 36 F CLL RIC PBSC MMUD þ
7 59 M AML RIC UCB MUD 
8 64 M NHL RIC UCB MUD þ
9 28 M CVID RIC PBSC MUD þ
10 51 F MM RIC PBSC MUD þ
11 65 M CLL RIC PBSC MUD þ
12 60 F CLL RIC PBSC MUD þ
13 37 M MDS RIC UCB MUD 
14 65 M NHL RIC PBSC MUD 
15 55 M MDS RUC PBSC MUD 
16 41 F AML RIC UCB N/A 
17 66 M CLL RIC PBSC MUD 
aGHVD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host
conditioning; BM, bone marrow; MUD, matched unrelated donor; n/a, not availabl
NHL, non-Hodgkin lymphoma; MAC, myeloablative conditioning; MDS, myelodys
unrelated donor; CVID, common variable immunodeﬁciency syndrome; MM, multElectronic medical records and high-resolution digital photographs
were reviewed, and datawere collected using a standardized collection form
and entered into a Microsoft Excel spreadsheet (Microsoft Corporation,
Redmond, WA). Data were collected based on the following 5 categories: (1)
transplantation demographics (eg, diagnosis, conditioning regimen, and
GVHD prophylaxis), (2) relevant indicators of medical status at time of onset
of oral ulcers (eg, absolute neutrophil count, immunosuppressive medica-
tion regimen, sirolimus dose, and serum levels), (3) clinical parameters of
the initial oral ulcer episode (eg, time to onset, oral sites affected, and
severity), (4) clinical trajectory of themost persistent (“sentinel”) lesion, and
(5) management and time to complete resolution. Descriptive statistical
analyses (medians, ranges, and totals) were performed using STATA, version
9.2 (Stata Corp, College Station, TX). Linear regression was used to explore
the associations between sirolimus level and the number, severity, and/or
duration of oral ulcers. All P values were considered to be statistically sig-
niﬁcant at P < .05.RESULTS
Patient Characteristics
This study included 17 patients with a median age of 58
years (range, 28 to 66 years) (Table 1). All study patients
underwent allogeneic HSCT at Dana-Farber/Brigham and
Women’s Cancer Center for management of underlying
hematologic malignancies, with the majority receiving
reduced-intensity conditioning regimens (15 of 17; 88.2%)
and matched unrelated donor stem cell grafts (15 of 17;
93.8%). All patients received a combination of sirolimus and
tacrolimus for GVHD prophylaxis beginning on day -3.
Tacrolimus was initiated at a dose of .02 mg/kg/day by
continuous intravenous infusion, adjusted to maintain a
serum concentration of 5 to 10 ng/mL. Sirolimus was initi-
ated with a 12 mg oral loading dose, followed by a daily oral
dose of 4 mg, adjusted to maintain a serum trough concen-
tration of 3 to 12 ng/mL.
Four patients reported a prior history of infrequent (ie,
less than 6 ulcers per year) recurrent aphthous stomatitis.
One patient developed conditioning regimen-associated oral
mucositis that had fully resolved and healed before the onset
of aphthous-like oral ulcers. None of the patients presented
with GVHD at the time of onset of oral ulcers. Six patients
developed acute GVHD. Eight patients developed systemicTime of
Onset after
HSCT, d
Maximum
aGVHD
Grade
cGVHD Time of
Onset after
HSCT, d
cGVHD Organ
Involvement
0 þ 181 n/a
0 
0 
0 
0 
n/a 3 þ 189 Skin, eyes, mouth
0 þ 209 n/a
30 1 
65 3 
44 2 þ 313 Skin, mouth
71 2 þ 209 Skin, eyes, mouth
103 2 
0 
0 þ 22 Skin, eyes, mouth, lung,
liver, musculoskeletal,
hematologic, soft tissue
0 
0 þ 157 Skin, eyes, mouth
0 þ 216 n/a
disease; M,male; AML, acutemyelogenous leukemia; RIC, reduced-intensity
e; CLL, chronic lymphocytic leukemia; UCB, umbilical cord blood; F, female;
plastic syndrome; PBSC, peripheral blood stem cells; MMUD, mismatched
iple myeloma.
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A. Villa et al. / Biol Blood Marrow Transplant 21 (2015) 503e508 505chronic GVHD and 5 of them developed oral chronic GVHD at
a later stage (Table 1).
Medical Status at the Time of Onset of Oral Ulcers
Patients presentedwith amedian sirolimus serum level of
8.4 ng/mL (range, 3.6 to 60.0 ng/mL; therapeutic range, 3 to
12 ng/mL). Sirolimus serum levels were found to be supra-
therapeutic (ie, >12 ng/mL) in 3 patients. All remaining
patients were within therapeutic range. Sirolimus serum
levels were not associated with the number (P ¼ .20),
severity (P ¼ .84), or duration of oral ulcers (P ¼ .76; data not
shown). Fourteen of the 17 patients were receiving concur-
rent immunosuppression with tacrolimus (n ¼ 11), myco-
phenolate mofetil (n ¼ 2), and budesonide (n ¼ 1) (Table 2).
Of these 14 patients, 3 had undergone dose reductions in
their immunosuppressive regimens during the 2 weeks
before onset of oral ulcers. Tacrolimus serum levels were
found to be subtherapeutic in 1 of these patients as well as in
5 additional patients whose tacrolimus doses had not
otherwise been tapered. All but 2 patients had absolute
neutrophil counts > 1000 cells/mL.
One patient developed acneform eruption of the chest
and neck secondary to sirolimus use. No other sirolumus-
associated toxicities were reported.
Characteristics of Oral Ulcerations
All observed oral ulcers had an aphthous-like appearance,
with well-demarcated borders and focal perilesional ery-
thema (Figure 1). Patients presented with a median of 2
ulcers (range, 1 to 8) with a median time to onset of day þ55
after allogeneic HSCT (range, 6 to 387 days) (Table 2). The
most common site for ulceration was the ventrolateral
tongue (76.5% of all ulcers), followed by the buccal mucosa
(29.4%), labial mucosa (23.5%), and soft palate (23.5%); 92.9%
of ulcers affected nonkeratinized mucosa. Three ulcers
arising in 3 different patients developed on the keratinized
tissue of the tongue dorsum, with all 3 patients also devel-
oping ulcers on nonkeratinized sites. The histopathology of
the ulcers in the 5 patients who underwent biopsy was
nonspeciﬁc (Figure 2). Each consisted of ﬁbrin with
enmeshed neutrophils and underlying granulation tissue
with acute and chronic inﬂammation that extended into the
underlying skeletal muscle with associated myositis and
muscle fragmentation. Therewas no viral cytopathic effect in
the adjacent intact epithelium.
In each patient, the single most persistent and/or severe
ulcer was classiﬁed as a sentinel lesion (Table 3). All sentinel
lesions were located on nonkeratinized mucosa, with nearly
one-half (n ¼ 8) occurring on the ventrolateral tongue. The
median diameter was 1.0 cm (range, .25 to 3.0 cm), with 7 of
the lesions classiﬁed as major (>1.0 cm) and 9 classiﬁed as
minor (1.0 cm). Patients reported a median pain score of 8
(range, 0 to 10); the patient who provided a pain score of zero
was being treated with oxycodone for pain control and
reported “generalized discomfort.”
Management of Oral Ulcers
All patients received treatment for management of
oral ulcers and returned for at least 1 follow-up visit.
Anesthetic “magic mouthwash” (lidocaine/aluminum hy-
droxide, magnesium hydroxide, and dimethicone suspen-
sion/diphenhydramine; equal parts) was used as accessory
palliative treatment for pain management before initiating
steroid therapy in 11 of the 17 patients.
Figure 1. Fifty-four year-old female with a history of acute myeloid leukemia
after HSCT on sirolimus and tacrolimus who developed 2 painful aphthous-like
tongue ulcers.
A. Villa et al. / Biol Blood Marrow Transplant 21 (2015) 503e508506Patients were treated with topical (n ¼ 13), intralesional
(n ¼ 12), and/or systemic (n ¼ 1) corticosteroid therapy
(Table 3). Topical corticosteroids (clobetasol .05% gel and
dexamethasone .1 mg/mL solution) were used 2 to 4 times
per day. Clobetasol gel was applied locally to lesions,
whereas dexamethasone solution was rinsed for 5 minutes
and expectorated. Of the 13 patients who received topical
corticosteroid treatment, 12 of these patients were also
treated with intralesional triamcinolone acetonide injections
(Kenalog 40, Bristol-Myers Squibb, Princeton, NJ), receiving a
median of 1 intralesional steroid injection (range, 1 to 4),
with a median of 7 days between injections (range, 4 to 15
days) for those receiving multiple procedures. All of
the patients managed with intralesional steroid therapy
reported immediate symptomatic improvement (minutes to
hours after the procedure), with no adverse events reported.
In addition to topical and intralesional steroid therapy, 1
patient was treated with high-dose systemic prednisone (1.0
mg/kg) for 1 week because of severe symptoms. There were
no adverse events secondary to corticosteroid treatment.
Median time to complete resolution of oral ulcerations
(inclusive of the sentinel ulcers) after initiation of cortico-
steroid treatment was 14 days (range, 2 to 70 days). One
patient with a large (>3.0 cm) ulcer received 4 intralesional
steroid injections and ultimately experienced complete res-
olution after 70 days, although there was signiﬁcant symp-
tomatic improvement before complete healing.Figure 2. Histological features of oral mucosa exhibiting deep ulcer involving muscle
myositis (B).No patients underwent sirolimus dose reductions or
discontinuation because of oral ulcers. Two patients had
their sirolimus dose tapered 2 weeks after the ﬁrst visit as
part of their immunosuppression tapering schedule, but they
otherwise remained on sirolimus therapy (data not shown).DISCUSSION
We report a series of patients who developed sirolimus-
associated oral aphthous-like ulcerations in the context of
GVHD prophylaxis after allogeneic HSCT. From our limited
case series, it is impossible to determine causality, and actual
incidence and potential associated risk factors remain to be
elucidated. However, aphthous-like ulcerations are other-
wise an unexpected oral complication after allogeneic HSCT
and the clinical features and management outcomes
described in this series are otherwise similar to other reports
characterizing mTOR-associated stomatitis [22]. It is impor-
tant that HSCT clinicians are aware of this possible
complication so that unnecessary tests, procedures, and
prescriptions can be avoided, and appropriate supportive
care be instituted in timely fashion.
Aphthous-like oral ulceration associated with sirolimus
therapy was initially described in the solid organ trans-
plantation literature [17,19]. However, it was not until the
use of mTOR inhibitor “rapalogs” for the treatment of cancer
that this oral toxicity was ﬁrst comprehensively character-
ized. Sonis et al. provided a complete description of oral
ulcers secondary to mTOR inhibitor therapy in cancer pa-
tients and proposed the term “mTOR inhibitor-associated
stomatitis” (mIAS) to differentiate from oral mucositis due
to conventional chemotherapy and/or radiation treatment
[18]. Development of this toxicity has been shown to be
dose dependent. In an international phase III study in renal
transplant recipients, patients were randomly assigned to
receive cyclosporine and a corticosteroid, plus a daily dose
of either 2 or 5 mg of sirolimus (oral emulsion) or a placebo.
Aphthous-like ulcerations were more prevalent in the high-
dose sirolimus group (5 mg/day; 42 of 208, 20.2%) when
compared with the lower dose group (2 mg/day; 22 of 219,
10.1%) [19]. In a large cross-sectional study in renal trans-
plant recipients receiving sirolimus (de novo therapy or
conversion from cyclosporine to sirolimus), 60% developed
oral ulcerations with a median time to onset of 1 week after
initiation of sirolimus therapy (range, 1 day to 15 months)
[17]. Onset of oral ulcers has also been associated with
conversion from tacrolimus to sirolimus (9 of 15) in
renal transplant recipients on steroid-free maintenance
therapy [20].at the base (A) and granulation tissue with acute and chronic inﬂammation and
Table 3
Clinical Course of Sentinel Oral Ulcer
Patient Location Diameter, cm Palliative
Treatment
Topical
Corticosteroid
Therapy
Intralesional
Corticosteroid
Therapy
No. Injections Total Dose of
Intralesional
Steroids, mg
Systemic
Corticosteroid
Therapy
Days to
Resolution
from Start of
Treatment
1 Lateral tongue 1.0  þ þ 3 60  28
2 Labial mucosa 1.5 þ þ þ 4 92  38
3 Labial mucosa 3.0  þ þ 4 60  70
4 Ventral tongue 0.5 þ þ þ 1 16  2
5 Lateral tongue 2.0 þ þ þ 2 32  21
6 Buccal mucosa 2.0 þ þ þ 3 52 þ 21
7 Lateral tongue 1.0 þ þ þ 2 36  49
8 Soft palate 2.5  þ þ 1 20  14
9 Soft palate 2.0 þ      19
10 Buccal mucosa 1.5  þ þ 1 10  14
11 Ventral tongue 0.5 þ þ     9
12 Ventral tongue 0.25 þ  þ 1 12  7
13 Soft palate 0.25  þ     7
14 Ventral tongue 1.0 þ þ þ 1 20  21
15 Buccal mucosa 0.75 þ      7
16 Ventral tongue 0.7 þ þ þ 1 N/A  5
17 Buccal mucosa N/A       7
A. Villa et al. / Biol Blood Marrow Transplant 21 (2015) 503e508 507The development of mIAS in the context of GVHD pro-
phylaxis with sirolimus appears to be a relatively infrequent
complication. However, patients were referred on a case-by-
case basis, and it may be that very mild cases were not
referred for evaluation and management, and therefore,
were excluded from this analysis. As such, the overall inci-
dence rate of 1.8% (17 of 967) is likely underestimated. The
median time to onset of ulcerations in our patient population
was 55 days after allogeneic HSCT (range, 6 to 387 days). One
patient developed mIAS at day þ387 after sirolimus therapy
was restarted (with a 12 mg loading dose) for active GVHD
management. Overall, the median time to development of
oral ulcers was longer when compared with another study in
oncology settings (55 days versus 10 days) [22]. The reason
for this discrepancy is unclear but may be related to the
conditioning regimen and/or concomitant immunosup-
pressive therapy providing a possible protective role. As
immunosuppressive medications are effective in managing
recurrent aphthous stomatitis that is not associated with
sirolimus or any other medication, it is possible that, at least
in some cases, subtherapeutic tacrolimus levels and/or
tapering of other immunosuppressive medications may have
contributed to the development of oral ulcerations.
Clinically, oral ulcers secondary to sirolimus for GVHD
prophylaxis were similar to those reported in other mIAS
cases in solid organ transplant settings [17,19,20]. Oral ulcers
were mostly small (<1 cm) shallow, ovoid, or round, and
covered by a grayish-yellow ﬁbrin pseudomembrane with an
erythematous halo, similar to aphthous ulcers, as charac-
terized in previous reports of mIAS [18,22]. Ulcers were
largely restricted to the nonkeratinized mucosa (92.9% of
ulcers), with the ventrolateral tongue being the most
frequently affected site, suggesting that trauma (eg, acci-
dentally biting the side of the tongue) is at least in part a
contributing factor (as is the case with classic recurrent
aphthous stomatitis) [23]. Treatment for mIAS includes
localized administration of high-potency corticosteroids,
nonsteroidal anti-inﬂammatory drugs, and/or topical anes-
thetics [22]. In a retrospective analysis of 17 oncology pa-
tients being treated with rapalogs who developed mIAS, all
individuals experienced a complete response with intrale-
sional corticosteroid injection and/or topical steroids (with 1
patient also receiving a short course of systemic steroids)without modiﬁcation or discontinuation of mTOR inhibitor
therapy. All patients reported signiﬁcant reduction in sym-
ptoms after initiation of therapy, and median time to com-
plete resolution of mIAS after initiation of corticosteroid
treatment was 14 days (range, 2 to 70 days). Other studies in
solid organ transplantation settings reported complete res-
olution of mIAS in 2 weeks after discontinuation of sirolimus
and/or substitution with cyclosporine or tacrolimus [17,20].
Notably, the study by MacDonald et al. demonstrated that all
patients were reported to experience spontaneous healing
without speciﬁc intervention or dose modiﬁcations [19].
There are a number of limitations in interpreting
these ﬁndings. This was a small, single-center, case-based
retrospective study. Without prospective assessment, it is
impossible to determine the true incidence of oral ulcers in
this clinical setting. Despite the known association with
sirolimus therapy and the development of oral aphthous-like
ulcerations, there may have been other potentially contrib-
uting factors. Both acute and chronic GVHDmay presentwith
oral ulcerations, but these do not typically have an aphthous-
like appearance and none of the patients had other ﬁndings
suggestive of GVHD [24]. Recrudescent herpes simplex virus
infection may present with similar clinical features; how-
ever, all viral cultures were negative and all patients were
taking acyclovir prophylaxis. Finally, sirolimus levels were
within therapeutic range, around the time of onset of oral
ulcers, yet in some studies this toxicity has been shown to be
dose dependent. However, persistent higher serum levels of
sirolimus in the days before the onset of oral ulcers may have
contributed to the number of ulcerations and severity
of symptoms present at the ﬁrst visit. Although therapy
with corticosteroids appeared to be effective, randomized
placebo-controlled studies are necessary to determine the
true clinical course and efﬁcacy of therapy.
Oral aphthous-like ulcerations appear to be an infre-
quent yet potentially debilitating toxicity associated with
sirolimus-containing GVHD prophylaxis regimens in patients
undergoing allogeneic HSCT. Early diagnosis may result in
better outcomes and the need for shorter therapeutic inter-
vention. In most cases, it appears that with adequate local-
ized intervention, this complication has a ﬁnite duration and
sirolimus dosing does not generally require modiﬁcation.
Further research is needed to determine risk factors and
A. Villa et al. / Biol Blood Marrow Transplant 21 (2015) 503e508508prediction of sirolimus-associated oral aphthous-like ulcer-
ations in the context of GVHD prophylaxis after alloge-
neic HSCT.
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